Business Model: Initially a generic pharmaceutical company relying on reverse-engineering patented drugs, Cipla shifted post-2005 due to stricter patent laws. It now emphasizes organic growth, selective strategic alliances, and increased exports to Western markets, alongside R&D for niche products. The company operates two segments: Pharmaceuticals (core revenue driver) and New Ventures (consumer healthcare, biosimilars).
Financials: Cipla reported ₹25,774 crore in revenue and ₹4,154 crore in net profit in FY24, with a 25.1% CAGR in profit growth over five years. It maintains low debt (₹559 crore) and a healthy dividend payout of 22%.
Strategic Initiatives: Cipla has expanded through acquisitions (e.g., Ivia Beaute’s cosmetics business for ₹130 crore in 2024) and innovation, launching products like Spirofy (wireless spirometer) and CIPREMI (Remdesivir). Its U.S. subsidiary, Cipla USA, drives growth in complex generics, while Cipla Health Limited strengthens its consumer healthcare portfolio.
Challenges: Cipla faces regulatory hurdles, modest sales growth (9.51% over five years), and competition from global giants. Promoter holding has decreased by 4.43% in recent years, signaling potential vulnerabilities.
Latest News on Cipla
Cipla Health ventures into sexual wellness sector with introduction of Unfold brand
Cipla Health, a leading consumer healthcare company in India, has launched a new brand called Unfold, which marks its entry into the sexual wellness category. Unfold aims to promote openness, trust, and choice in intimate wellbeing, and its visual identity was developed in collaboration with dCell, the design arm of MullenLowe Lintas Group. The goal was to create a modern and distinctive look that would set a fresh tone for the category and stand out among global condom labels.
According to Shivam Puri, Managing Director and CEO of Cipla Health, the company is committed to providing wellness products that enhance overall health and wellbeing. With Unfold, the company has entered the sexual wellness category with products guided by strong consumer insights, where trust is a paramount consumer need. The packaging design plays a crucial role in establishing brand credentials, and dCell has translated these insights into a modern packaging design that feels fresh and reframes intimacy while staying stigma-free.
The design of Unfold’s logo and packaging is inspired by the idea of “unfolding” layers of passion and intimacy. The bold, vibrant colors and dynamic design system evoke excitement and desire, while a metallic holographic finish adds a layered, premium appeal. Bhumika Shah, Executive Design Director at dCell, notes that Unfold is more than just a product – it’s a step towards normalizing conversations around intimacy in India. The brand’s stylish, modern, and aspirational identity reflects a growing demand for sexual wellness products that are discreet, aesthetically appealing, and uncompromising on quality.
The response to Unfold has been encouraging, with both consumers and trade partners showing positive feedback. The brand is on its journey to deliver real impact and promote a more open and stigma-free conversation around intimacy in India. With Unfold, Cipla Health aims to provide a fresh perspective on the sexual wellness category and establish itself as a leader in the market. The brand’s modern and distinctive design is expected to appeal to a new generation of consumers who are looking for products that are both effective and aesthetically pleasing.
Cipla Health and MullenLowe’s dCell launch new brand focused on sexual wellness
Cipla Health, a leading healthcare company, has launched a new brand called Unfold, marking its entry into the sexual wellness segment. The brand’s design and visual identity were developed by dCell, a design agency, to redefine how intimacy is represented in India’s healthcare market. Unfold’s packaging features a modern and minimal aesthetic, positioning the brand alongside global names in the sexual wellness space while resonating with Indian consumers.
According to Shivam Puri, Managing Director and CEO of Cipla Health, the launch of Unfold is a significant step towards providing wellness products that focus on enhancing overall health and wellbeing. The company conducted extensive consumer research to understand the needs and preferences of Indian consumers, and the findings guided the development of Unfold’s product offerings. Puri emphasized that trust is a paramount consumer need in the sexual wellness category, and packaging plays a crucial role in establishing brand credentials.
The packaging design of Unfold was created to be fresh, modern, and stigma-free. The design features bold, vibrant colors and a dynamic system that evokes excitement and desire. A metallic holographic finish adds a premium appeal to the packaging. Bhumika Shah, Executive Design Director at dCell, explained that Unfold is more than just a product – it’s a step towards normalizing conversations around intimacy in India. The brand’s design reflects a growing demand for sexual wellness products that are discreet, aesthetically appealing, and uncompromising on quality.
With the launch of Unfold, Cipla Health expands its wellness portfolio and addresses evolving consumer attitudes towards intimacy and self-care. The brand’s design-forward approach bridges functionality and emotion, offering a unique and refreshing perspective on the sexual wellness category. The response from consumers and trade partners has been encouraging, and Unfold is poised to make a significant impact in the market. Overall, Unfold represents a significant step forward in promoting healthy and open conversations about intimacy and sexual wellness in India.
Cipla Enters India’s Weight-Loss Segment with ‘Yurpeak’, a Repurposed Version of Mounjaro
India’s weight-loss market has welcomed a new player with the launch of ‘Yurpeak’ by Cipla, a popular pharmaceutical company. Yurpeak is the brand name given to the medication Mounjaro, which has been approved by the US FDA for the treatment of type 2 diabetes. However, its effectiveness in weight loss has also been widely recognized. With the introduction of Yurpeak, Cipla aims to tap into the growing demand for weight-loss solutions in India.
Mounjaro, the original medication, is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood sugar levels and promotes weight loss. Clinical trials have shown that Mounjaro can lead to significant weight loss, with some patients losing up to 15-20% of their body weight. This has generated significant interest in the medication as a potential treatment option for obesity.
Cipla’s entry into the weight-loss market with Yurpeak is strategic, given the increasing prevalence of obesity and related health issues in India. The country is home to a large population struggling with weight-related problems, and the market for weight-loss solutions is expected to grow significantly in the coming years. By launching Yurpeak, Cipla is poised to capitalize on this trend and establish itself as a major player in the Indian weight-loss market.
The launch of Yurpeak is also expected to increase awareness about the importance of weight management and the availability of effective treatment options. Cipla plans to promote Yurpeak through a targeted marketing campaign, highlighting its benefits and effectiveness in weight loss. The company will also engage with healthcare professionals to educate them about the medication and its potential to address the growing obesity epidemic in India.
While the launch of Yurpeak is a significant development in India’s weight-loss market, it is essential to note that the medication should only be used under medical supervision. As with any prescription medication, there may be potential side effects and risks associated with Yurpeak, and patients should consult their healthcare provider before starting treatment.
In conclusion, the launch of Yurpeak by Cipla marks a new era in India’s weight-loss market. With its proven effectiveness in weight loss and Cipla’s strong presence in the Indian pharmaceutical market, Yurpeak is expected to make a significant impact on the country’s obesity landscape. As the demand for weight-loss solutions continues to grow, Cipla is well-positioned to capitalize on this trend and establish itself as a leader in the Indian weight-loss market.
Cipla receives a specialized commemorative stamp from India Post, celebrating its 90th anniversary.
Cipla, a leading Indian pharmaceutical company, has been honored with a customized stamp released by India Post to commemorate its 90th anniversary. The ₹5 stamp features the image of Dr. YK Hamied, a doyen of Cipla, with the company’s recent Mumbai office as the backdrop. The release of the stamp was attended by Dr. Hamied, his brother MK Hamied, and other Cipla employees, and was also live-streamed to the company’s global offices and sites.
The stamp was released by Suchita Joshi, Postmaster General of Navi Mumbai, in September, although the company had actually turned 90 in August. This milestone is a significant achievement for Cipla, which has established itself as one of the leading generic pharmaceutical companies in India and across the world. The company has a strong presence in Africa, the USA, Europe, and other selected markets.
Dr. Hamied had earlier stated that Cipla would continue to provide accessible and quality products to India and the world. He also outlined the company’s future focus areas, including respiratory, cardiac, cancer, obesity, and mental health segments, as well as anti-microbials. This is not the first time a pharmaceutical company has been honored with a customized stamp in India. Earlier this year, GlaxoSmithKline (GSK) had a stamp released to mark its 100 years in the country.
The release of the customized stamp is a testament to Cipla’s contributions to the pharmaceutical industry and its commitment to providing quality products to patients worldwide. As the company looks to the future, it is likely to continue playing a significant role in shaping the global healthcare landscape. With its strong presence in various markets and its focus on critical therapeutic areas, Cipla is well-positioned to address the evolving healthcare needs of patients around the world. The company’s 90th anniversary is a significant milestone, and the customized stamp is a fitting tribute to its achievements.
How He Transformed Cipla into a Worldwide Pharmaceutical Powerhouse
Yusuf Hamied, the Chairman of Cipla, is a leader who has transformed the global pharmaceutical landscape by advocating for affordable medications and lifesaving therapies. Born on July 25, 1936, in Vilnius, Lithuania, Hamied moved to India with his family and later studied Natural Sciences at Christ’s College, Cambridge, and earned his PhD in Organic Chemistry from the University of Cambridge. His experiences in science and the international community shaped his mindset, and he disagreed with the traditional pharma leaders who prioritized profit over people.
Before Hamied took over, Cipla was a respected Indian company with limited international influence. However, under his leadership, Cipla expanded its reach to over 80 countries, providing medications not just in India but also in Africa, Latin America, Europe, and Asia. Hamied’s vision was to introduce affordable global healthcare, and he achieved this by providing antiretroviral medications for HIV/AIDS at a price of $1 per day, shocking the powerful pharmaceutical companies in the West.
Hamied’s leadership was marked by innovation, and he invested in cutting-edge biotechnology and biosimilars. He created world-class manufacturing in India with quality equal to international standards. Cipla’s global impact was significant, and the company became a leader in providing affordable treatments for HIV/AIDS, COVID-19, respiratory care, and cancer. Today, Cipla is active in over 80 countries, with over 25,000 employees and a revenue of ₹22,000 crore+ (approx. 2.7 billion USD).
Despite facing challenges such as patent issues and regulatory regulations, Hamied remained guided by his moral compass, which emphasized compassion, innovation, and access. He believed that healthcare is a right, not a privilege, and that values have a longer-term impact than quarterly profits. Hamied’s journey is a testament to the fact that humanity and commercial viability can go hand in hand, and he has demonstrated that success is not just defined by numerics but by the lives changed and the positive impact created.
Hamied’s legacy is a challenge to future entrepreneurs and corporate leaders to redefine the societal role of business. His bravery in challenging global corporations and his assertion that healthcare is a fundamental human right make him one of India’s most transformative leaders today. As the Chairman of Cipla, Hamied continues to promote affordable access to essential medicines, and his work has saved millions of lives worldwide. His story is a reminder that business can be a force for good, and that leaders like Hamied can make a significant impact on the world.
Stock Market Updates for Cipla
Recent Updates
Shivam Puri, Managing Director and CEO of Cipla Health Ltd, to serve on the Grand Jury for IMA 2025, as reported by Exchange4Media.
The Indian Media Awards (IMA) 2025 Grand Jury consists of esteemed industry professionals, including Shivam Puri, Managing Director & CEO of Cipla Health Ltd. As reported by Exchange4Media, the IMA 2025 aims to recognize and celebrate excellence in the media industry.
Shivam Puri, with his extensive experience in the healthcare sector, brings a unique perspective to the Grand Jury. As the CEO of Cipla Health Ltd, he has been instrumental in shaping the company’s strategy and driving growth. His expertise in marketing, sales, and product development will be valuable assets to the jury.
The IMA 2025 Grand Jury will be responsible for evaluating entries across various categories, including media planning, media buying, and media research. The jury will assess the entries based on criteria such as innovation, creativity, and effectiveness. With Shivam Puri on board, the jury will have a comprehensive understanding of the healthcare sector and its media requirements.
The Indian Media Awards have been a benchmark for excellence in the media industry for several years. The awards recognize and reward outstanding work in media, and the Grand Jury plays a crucial role in selecting the winners. The jury’s decisions are based on a rigorous evaluation process, ensuring that the winners are truly deserving of the recognition.
The inclusion of Shivam Puri in the IMA 2025 Grand Jury is a testament to his reputation as a thought leader in the healthcare industry. His participation will not only bring a new perspective to the jury but also ensure that the awards are given to the most deserving candidates. As the media industry continues to evolve, the IMA 2025 will provide a platform for professionals to showcase their work and be recognized for their achievements.
The Exchange4Media report highlights the importance of the IMA 2025 and the role of the Grand Jury in selecting the winners. With Shivam Puri as part of the jury, the awards are expected to be even more competitive and prestigious. The IMA 2025 will be a significant event in the media industry, and the participation of industry leaders like Shivam Puri will make it a memorable occasion. Overall, the IMA 2025 Grand Jury, including Shivam Puri, will play a vital role in recognizing and celebrating excellence in the media industry.
Dr Sharvil Patel of Zydus Lifesciences assumes the role of President at the Indian Pharmaceutical Association
Zydus Lifesciences’ Managing Director, Dr. Sharvil Patel, has taken over as the new President of the Indian Pharmaceutical Alliance (IPA). The IPA is a coalition of Indian pharmaceutical companies that aims to promote the interests of the domestic pharmaceutical industry.
As the President of the IPA, Dr. Patel will play a key role in shaping the organization’s policies and advocating for the interests of the Indian pharmaceutical industry. Under his leadership, the IPA is expected to focus on issues such as promoting innovation, improving access to medicines, and enhancing the competitiveness of the Indian pharmaceutical industry.
Dr. Patel brings a wealth of experience to the role, having served as the Managing Director of Zydus Lifesciences since 2014. During his tenure, Zydus Lifesciences has grown significantly, with a strong focus on research and development, manufacturing, and marketing of pharmaceutical products.
The Indian pharmaceutical industry is one of the largest and most competitive in the world, with a strong presence of domestic companies such as Zydus Lifesciences, Sun Pharma, and Cipla. The industry has been growing rapidly, driven by factors such as a large and growing population, an increasing burden of diseases, and a strong regulatory framework.
However, the industry also faces several challenges, including intense competition, pricing pressures, and regulatory hurdles. As the President of the IPA, Dr. Patel will need to navigate these challenges and work with stakeholders, including the government, regulators, and industry players, to promote the interests of the Indian pharmaceutical industry.
Dr. Patel’s appointment as the President of the IPA has been welcomed by the industry, with many stakeholders expressing confidence in his ability to lead the organization and promote the interests of the Indian pharmaceutical industry. His experience, expertise, and vision are expected to be valuable assets to the IPA, and his leadership is likely to have a positive impact on the industry as a whole.
Overall, Dr. Sharvil Patel’s appointment as the President of the IPA is a significant development for the Indian pharmaceutical industry. With his experience, expertise, and vision, he is well-positioned to lead the organization and promote the interests of the industry. As the industry continues to grow and evolve, Dr. Patel’s leadership will be critical in navigating the challenges and opportunities that lie ahead.
China’s reduction in import duties helps alleviate the impact of US tariffs on India’s pharmaceutical industry.
The Indian pharmaceutical industry is facing a complex global trade landscape, with contrasting developments in China and the US. China has reduced import duties on Indian pharma products by 30%, effectively enabling near-zero-cost access, providing a significant growth opportunity in a key Asian market. On the other hand, the US has announced a 100% tariff on imported branded and patented drugs, effective October 2025, which will put pressure on Indian companies reliant on US sales.
Companies such as Aurobindo Pharma, Lupin, and Sun Pharma have high US revenue exposure, making them vulnerable to the tariff. Aurobindo Pharma has a 46.7% exposure, Lupin has 35.8%, and Sun Pharma has 32.7%. In contrast, companies like Cipla, with a 14.1% exposure, are relatively insulated due to their focus on generics.
The US tariff primarily targets branded and patented drugs, which may exempt generics. However, the uncertainty surrounding the tariff’s scope and impact on generics can impede strategic planning and operational continuity. China’s reduced import duties, on the other hand, significantly improve the cost competitiveness of Indian exports, offering a valuable alternative market to mitigate US exposure.
To navigate this complex landscape, Indian pharmaceutical companies should consider strategic adjustments, such as portfolio segmentation, market diversification, and capex and manufacturing strategy. They should distinguish between US tariff-sensitive products and less vulnerable categories, expand their footprint in China and other Asian markets, and consider US production facilities to gain tariff exemptions.
Companies can leverage China’s favorable policies to diversify revenue streams, enhance margins, and mitigate geopolitical trade risks. Continuous monitoring of policy developments, revenue allocations, and strategic investments will be critical for Indian pharma to sustain global competitiveness in this dynamic landscape. By doing so, Indian pharmaceutical exporters can capitalize on growth opportunities in China and other markets, while minimizing the impact of the US tariff on their business.
Generic pharmaceutical companies dodge significant damage, avoiding a medical emergency.
India’s generic pharmaceutical companies are likely to continue business as usual despite US President Donald Trump’s 100% levy on pharmaceuticals. The tariff is targeted at branded and patented medicines, which may not directly impact generic companies. However, some companies like Sun Pharma, which generates a significant portion of its revenue from patented drugs in the US, may face headwinds. Sun Pharma’s drug sales in the US totalled $1.1 billion in FY25, accounting for around 17% of its total revenue.
Companies with manufacturing bases in the US, such as Sun Pharma, Dr Reddy’s, and Cipla, may shift production of higher-value specialty and niche drugs from India to their American facilities to cushion the blow. This move could drive companies to diversify export markets, recalibrate global strategies, and set up manufacturing bases in the US to safeguard access to the lucrative market.
Industry experts believe that Indian pharma companies need to diversify markets and innovate in complex generics and biosimilars to stay resilient in a changing global trade landscape. India’s pharma exports to the US were close to $10 billion last year, and the country services around 35% of US prescriptions with affordable generics. The Indian Pharmaceutical Alliance secretary general, Sudarshan Jain, emphasized that India plays a vital role in US healthcare by ensuring a steady supply of affordable medicines.
The pharma sector is awaiting more clarity on the announcement, as it did not specify whether specialty drugs, niche, or complex generic drugs are under its ambit. There is also uncertainty over the definition of “branded” drugs, which could impact companies like Granules India. Despite the uncertainty, experts believe that Indian pharma companies will need to reinforce their cost-efficiency advantage in bulk drugs and APIs, an area where the US is likely to favor India over other suppliers. They will also need to invest in next-generation opportunities, such as complex generics, peptides, and biosimilars, to remain competitive.
Cipla Group company InvaGen Pharmaceuticals partners with Bora Biologics for production of NYPOZI at their San Diego facility.
Bora Biologics has partnered with InvaGen Pharmaceuticals, a subsidiary of Cipla Group, to manufacture NYPOZI(TM) at its San Diego facility. This partnership marks a significant milestone in the production of NYPOZI(TM), a crucial medication for patients in need. Bora Biologics’ state-of-the-art facility in San Diego will be utilized to manufacture the drug, leveraging the company’s expertise in biologics manufacturing.
InvaGen Pharmaceuticals, as a Cipla Group company, brings extensive experience in pharmaceutical development and commercialization to the table. The collaboration between Bora Biologics and InvaGen Pharmaceuticals aims to ensure a stable and efficient supply chain for NYPOZI(TM), meeting the growing demand for this essential medication.
Under the terms of the partnership, Bora Biologics will be responsible for the manufacturing of NYPOZI(TM) at its San Diego facility, while InvaGen Pharmaceuticals will handle the regulatory and commercial aspects of the product. This strategic partnership will enable both companies to pool their resources and expertise, ultimately benefiting patients who rely on NYPOZI(TM) for their treatment.
The San Diego facility, where NYPOZI(TM) will be manufactured, is equipped with cutting-edge technology and staffed by experienced professionals. Bora Biologics’ commitment to quality and adherence to regulatory standards will ensure that NYPOZI(TM) is produced with the highest level of excellence.
This collaboration is a testament to the growing trend of partnerships in the pharmaceutical industry, where companies are coming together to leverage their strengths and expertise to bring essential medications to market. The partnership between Bora Biologics and InvaGen Pharmaceuticals is expected to have a positive impact on patients, healthcare providers, and the pharmaceutical industry as a whole.
With the manufacturing of NYPOZI(TM) at Bora Biologics’ San Diego facility underway, patients can expect a steady supply of this vital medication. The partnership between Bora Biologics and InvaGen Pharmaceuticals demonstrates the companies’ dedication to improving patient outcomes and advancing the field of biologics manufacturing. As the demand for NYPOZI(TM) continues to grow, this collaboration will play a critical role in ensuring that patients have access to the medication they need.
Umang Vohra set to step down, with Achin Gupta poised to succeed as new Global CEO.
In a significant development, Cipla, a leading pharmaceutical company, is undergoing a leadership shift. Umang Vohra, the current Managing Director and Global Chief Executive Officer (CEO), has decided to exit the company. Vohra’s departure marks the end of an era at Cipla, where he has been instrumental in shaping the company’s strategy and driving its growth over the past few years.
As Vohra prepares to leave, Achin Gupta, the current Chief Financial Officer (CFO), is likely to take over as the new Global CEO of Cipla. Gupta has been with the company for several years and has played a key role in driving its financial strategy and growth. His appointment as CEO is expected to be a smooth transition, given his familiarity with the company’s operations and his experience in the pharmaceutical industry.
Vohra’s decision to exit Cipla is seen as a surprise move, given his successful tenure at the company. During his leadership, Cipla has expanded its presence in global markets, launched several new products, and strengthened its research and development capabilities. Vohra has also been credited with driving the company’s digital transformation and building a strong leadership team.
The leadership shift at Cipla comes at a time when the company is facing intense competition in the pharmaceutical industry. The company has been investing heavily in research and development, and has been exploring new opportunities in areas such as biotechnology and digital health. Gupta’s appointment as CEO is expected to ensure continuity and stability at the company, and to drive its future growth and strategy.
Gupta’s background and experience make him an ideal candidate to lead Cipla. He has a strong track record of driving financial growth and has been instrumental in shaping the company’s strategy. He is also known for his leadership skills and his ability to build strong teams. With Gupta at the helm, Cipla is expected to continue its growth trajectory and to remain a major player in the pharmaceutical industry.
Overall, the leadership shift at Cipla marks a new chapter for the company. While Vohra’s exit is a loss, Gupta’s appointment as CEO is expected to ensure continuity and stability. With a strong leadership team and a clear strategy, Cipla is well-positioned to drive growth and innovation in the pharmaceutical industry. The company’s future looks bright, and investors and stakeholders will be watching with interest as Gupta takes over as Global CEO.
Umang Vohra, Managing Director of Cipla, is reportedly set to resign, with Chief Operating Officer Achin Gupta likely to take over his position.
Indian pharmaceutical company Cipla is reportedly preparing for a significant management change. Umang Vohra, the company’s managing director and global CEO, is expected to step down by the end of the current fiscal year. Vohra, 54, has been in the role for nearly a decade. Achin Gupta, currently Cipla’s global chief operating officer, is likely to take over as his replacement. According to an industry executive, Gupta has been groomed for the role over the past few years and is expected to assume the position by March 2026.
Cipla is a major player in the pharmaceutical industry, manufacturing active pharmaceutical ingredients for other companies, as well as a range of pharmaceutical and personal care products. The company is the world’s largest producer of antiretroviral drugs and has a significant presence in over 80 countries worldwide. In India, Cipla operates 34 manufacturing units across eight locations.
One of Cipla’s notable achievements was the launch of Remdesivir, an antiviral medication, under the brand name CIPREMI in July 2020. The medication was approved for “restricted emergency use” in critically ill COVID-19 patients, following a voluntary licensing agreement with Gilead Sciences and approval from the Drug Controller General of India (DCGI).
The management change is expected to take place over the next year, with Gupta likely to take over the role of managing director and global CEO. The transition is seen as a planned move, with Gupta having been prepared for the position over the past few years. The change is expected to have a significant impact on the company’s operations and strategy, although the exact details of the transition are not yet clear.
Cipla’s products include a range of medications, such as escitalopram oxalate, lamivudine, and fluticasone propionate. The company’s global presence and reputation as a major pharmaceutical manufacturer make it a significant player in the industry. As the company prepares for the management change, it will be interesting to see how the transition affects its operations and strategy in the coming months.
Teva Abandons Patent Dispute with Cipla Over Qvar Inhaler as FTC Pressures for Delisting
Teva Pharmaceutical Industries Ltd. has reached a settlement agreement to dismiss its patent-infringement lawsuit against Cipla Ltd., an Indian generic-drug maker, over proposed copies of its Qvar RediHaler asthma treatment. The agreement was approved by Judge Stanley R. Chesler in a consent order of dismissal issued in the US District Court for the District of New Jersey. The terms of the agreement were not disclosed, and neither Teva nor Cipla has commented on the matter.
Teva had filed the lawsuit in February 2024, seeking to block Cipla’s generic version of Qvar RediHaler, which is an inhalation aerosol used to treat asthma. The lawsuit alleged that Cipla’s proposed generic would infringe on Teva’s patents related to the medication. By settling the case, Teva has ended its efforts to prevent Cipla from launching a generic version of Qvar RediHaler, at least for the time being.
The agreement does not necessarily mean that Cipla will be able to launch its generic version of Qvar RediHaler immediately. The consent order of dismissal leaves the door open for either side to renew allegations in the future, suggesting that the dispute may not be fully resolved. Teva may still try to block Cipla’s generic version of Qvar RediHaler if it believes that Cipla’s product infringes on its patents.
The settlement is significant because it could impact the availability of affordable asthma treatments in the US. Qvar RediHaler is a prescription medication that is used to control and prevent symptoms of asthma. A generic version of the medication could provide a more affordable option for patients who rely on Qvar RediHaler to manage their asthma.
Overall, the settlement between Teva and Cipla highlights the complex and often contentious nature of patent disputes in the pharmaceutical industry. The agreement may have implications for patients, healthcare providers, and the pharmaceutical industry as a whole, and its impact will likely be closely watched in the coming months and years.
Prominent pharmaceutical companies such as Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, and Torrent Pharma are navigating the complexities of the pharma value chain.
The pharmaceutical industry is complex, with various segments such as innovator products, generics, branded generics, and API. Indian companies are making headway globally, and understanding the industry’s intricacies is crucial for those seeking opportunities. Innovator companies undertake significant risks, with only 8 out of 100 molecules crossing the finish line, and patent protection is the incentive for undertaking this risk. Roche, a leading innovator, reported a 30% PAT margin in FY24, with R&D expenses at 20% of sales.
Indian pharma is sustained by generics, but companies like Sun Pharma and Glenmark Pharma are making modest beginnings in innovation. Sun Pharma’s innovative medicine segment has 11 products, including Ilumya, which reported sales of $680 million in FY25. Glenmark Pharma’s Ichnos Glenmark Innovation (IGI) recently entered a licensing agreement with AbbVie for its ISB 2001, receiving $700 million in milestone payments.
The generics business is dependent on the level of competition, with prices declining sharply as the number of competitors increases. Branded generics, however, offer higher value, with companies like Mankind Pharma and Torrent Pharma generating significant revenues from their branded portfolios. Complex generics, such as Lupin’s generic Spiriva, hold a value proposition in regulated markets, with strong revenue streams and above-average margins.
Biosimilars are a growing segment, with companies like Biocon developing portfolios. The biosimilar approval process involves clinical trials, increasing the cost of development to $200-300 million. CRDMO (contract research and development and manufacturing outsourcing) is another emerging segment, with companies like Divi’s Labs and Anthem Biosciences securing a portion of the innovators’ drug development process.
The API business is largely commoditized, with prices dependent on tonnage. However, high-potent APIs and complex manufacturing processes can fetch higher margins. India has focused on API development with its PLI schemes, and companies like Aurobindo Pharma are establishing API facilities.
For investors, a strong branded generic base supplemented by a wide innovator portfolio is essential for trail-blazing growth. Complex generics and CRDMO are emerging sectors, with China+1 and the US Biosecure Act providing tailwinds. The right mix of business segments and prospects is crucial for growth, and understanding the industry’s intricacies is essential for those seeking opportunities in the pharmaceutical sector.
Key takeaways include:
* Innovator companies undertake significant risks, but patent protection provides an incentive.
* Indian pharma is sustained by generics, but companies are making modest beginnings in innovation.
* Branded generics offer higher value, with companies generating significant revenues from their branded portfolios.
* Complex generics hold a value proposition in regulated markets, with strong revenue streams and above-average margins.
* Biosimilars are a growing segment, with companies developing portfolios.
* CRDMO is an emerging segment, with companies securing a portion of the innovators’ drug development process.
* The API business is largely commoditized, but high-potent APIs and complex manufacturing processes can fetch higher margins.
Sun Pharma and Lupin are developing an anti-obesity oral medication to reduce costs and cater to those hesitant about injections.
The Indian pharmaceutical companies, Sun Pharma and Lupin, are developing oral semaglutide pills to address obesity and injection aversion. Currently, leading anti-obesity drugs like Mounjaro and Wegovy are available in injectable form, limiting accessibility and patient comfort. The Drugs Controller General of India (DCGI) has given Sun Pharma permission for a large-scale clinical trial to test its semaglutide tablets, while Lupin has received the green light for its bioequivalence study.
Obesity is becoming a significant public health challenge in India, with a projected 450 million overweight and obese adults by 2050. Experts believe that the injectable form of semaglutide is more effective for weight loss, but the oral variant could improve accessibility and patient comfort. Other Indian companies, such as Dr. Reddy’s Laboratories Ltd, Cipla Ltd, and Mankind Pharma, are also developing generic versions of semaglutide.
The development of these anti-obesity drugs is significant, and experts urge strict medical supervision and caution against misuse. Dr. Balram Bhargava, former director general of the Indian Council of Medical Research (ICMR), said that these drugs are “wonder drugs and novel inventions” but should be used under strict medical supervision. He added that irrational use of these drugs could have serious consequences and that they are suitable as a second line of treatment for individuals who are obese and diabetic.
The key takeaways from this development are:
1. Sun Pharma and Lupin are developing oral semaglutide pills to address obesity and injection aversion.
2. Regulatory approvals have been granted for Phase III trials and bioequivalence studies.
3. India faces an obesity burden of 450 million adults by 2050.
4. Experts urge strict medical supervision and caution against misuse.
5. Generic versions may flood the market next year, reshaping affordability and access.
Overall, the development of oral semaglutide pills and the upcoming availability of generic versions could significantly impact the treatment of obesity in India. However, it is crucial to ensure that these drugs are used responsibly and under strict medical supervision to avoid misuse and potential consequences.
Market Outlook for Generic Drugs in Saudi Arabia 2025-2033: Key Players Include Teva, Viatris, Sandoz, Sun Pharma, Cipla, Aurobindo Pharma, Lupin, Hikma Pharma, STADA Arzneimittel, and Dr. Reddy’s Labs.
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce pharmaceutical expenditure, and growing awareness of cost-effective alternatives. The market is also driven by local manufacturing and government support for generics.
The demand for generic medications in Saudi Arabia is increasing rapidly, driven by the government’s attempts to reduce reliance on imported branded medicines and lower healthcare spending. The Saudi Food and Drug Authority (SFDA) has simplified the process of generic approvals, encouraging local and foreign manufacturers to increase their generic offerings.
Key growth drivers in the Saudi Arabia Generic Drugs Market include government support and cost containment initiatives, increasing incidence of chronic diseases, and growing local production capability. The government has focused on making healthcare more affordable through greater generic drug promotion, and initiatives such as the “Procedure to deal with patents when registering generic products in SFDA” have been introduced to facilitate the growth of the generic drug market.
However, the market also faces challenges, including public perception and brand loyalty, as well as regulatory and quality control complexity. Despite these challenges, the market is expected to continue growing, driven by the increasing demand for cost-effective generic drugs.
The report provides an in-depth analysis of the Saudi Arabia Generic Drugs Market, including market trends, forecast, and key players analysis. The market is segmented by type, route of administration, therapeutic area, distribution channel, and region. Key players in the market include Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz Group AG, and Sun Pharmaceutical Industries Ltd.
The report also highlights the growing trend of online generic drugs in Saudi Arabia, with digital platforms and e-pharmacies facilitating easier price comparisons and prescription-based generics ordering for consumers. The online generic drug segment is expected to receive robust traction, particularly in urban regions such as Riyadh and Jeddah.
In terms of therapeutic areas, the report highlights the growing demand for generic drugs in areas such as respiratory, oncology, and infectious diseases. The report also provides an analysis of the regulatory framework of generic drugs in Saudi Arabia, including the role of the SFDA and the challenges faced by manufacturers in complying with regulatory requirements.
Overall, the Saudi Arabia Generic Drugs Market is expected to continue growing, driven by government support, increasing demand for cost-effective generic drugs, and growing local production capability. The report provides a comprehensive analysis of the market, including key trends, challenges, and opportunities, and is a valuable resource for companies looking to enter or expand their presence in the Saudi Arabian generic drugs market.
Pharma’s quest for expansion: Reaching out to the consumer’s doorstep
Several Indian pharmaceutical companies, including Cipla, Glenmark, Lupin, and Mankind Pharma, have demerged their consumer healthcare businesses to focus on growth and expansion. This trend is also being seen globally, with companies like GlaxoSmithKline, Johnson and Johnson, and Sanofi separating their consumer healthcare divisions. The rationale behind this strategy is to create a separate entity that can operate with a more agile and fast-moving consumer goods (FMCG) mindset, allowing for more focused marketing and advertising efforts.
According to Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, the company’s objective was to create a separate division for its over-the-counter (OTC) brands, which require a different environment, culture, and talent compared to prescription brands. The company had previously run its OTC business like its prescription business, but found that it was not effective. Juneja explains that some prescription brands can be transitioned to the consumer healthcare business within the regulatory framework, but everything should be different, including management, to stay focused and agile.
Subhakanta Bal, Managing Director and Head of Healthcare and Consumer at Rothschild & Co, notes that there are commonalities between consumer healthcare and the core prescription-driven business, but also differences. For example, consumer healthcare requires a more FMCG-like mindset, with a focus on marketing and advertising to drive sales. Bal observes that pharma companies often bring in FMCG veterans to run their consumer healthcare divisions, and that a separate entity can be more “fit for purpose”.
The pursuit of growth is the key reason behind the consumer healthcare demerging trend, according to Vishal Manchanda, Senior Vice-President at Systematix Group. Pharma companies are developing a second platform for growth, given the challenges in the domestic branded business and global uncertainties. However, it’s not an easy task, with intense competition from store-owned brands and pressure on prices.
The demerging of consumer healthcare businesses is expected to lead to better value realization, potentially through listing, as FMCG businesses in India trade at a higher value than domestic formulation businesses. Internationally, big pharma companies have separated or exited consumer healthcare to focus on innovation, but in India, the trend is driven by the need for right managerial talent, marketing, and advertising to ensure success. As the Indian pharmaceutical industry continues to evolve, the demerging of consumer healthcare businesses is likely to be a key strategy for growth and expansion.
Cipla’s CEO responds to tariff threats, highlighting the company’s diversified business model as a key strength.
Cipla, a leading pharmaceutical company, is confident in its ability to withstand the potential impact of tariff threats on its business. In a recent interview, Cipla’s CEO, Umang Vohra, emphasized that the company has “one of the most well-diversified models” in the industry, which would help mitigate the effects of tariff changes.
Vohra explained that Cipla’s diversified portfolio, which includes a mix of domestic and international businesses, would cushion the company from the potential fallout of tariffs. The company has a significant presence in various markets, including the US, Europe, and emerging markets, which would help spread the risk. Additionally, Cipla has a diversified product portfolio, with a range of therapies and products, including respiratory, cardiac, and anti-infective medicines.
The CEO also highlighted Cipla’s strong manufacturing capabilities, which would enable the company to adapt to changes in tariffs. Cipla has a robust manufacturing network, with facilities in India, the US, and other countries, which would allow the company to shift production to other locations if needed. This flexibility would help minimize the impact of tariffs on the company’s operations.
Vohra noted that while tariffs are a concern, they are not a new challenge for the company. Cipla has been navigating tariff changes and other trade-related issues for many years and has developed strategies to manage these risks. The company has a strong track record of adapting to changing market conditions and has a robust risk management framework in place.
Cipla’s diversified model and strong manufacturing capabilities have enabled the company to deliver consistent growth and performance, despite the challenges posed by tariffs and other factors. The company has reported strong revenue growth in recent quarters, driven by its domestic and international businesses.
In conclusion, Cipla’s CEO, Umang Vohra, is confident that the company’s diversified model and strong manufacturing capabilities would help mitigate the impact of tariff threats. With a diversified portfolio, robust manufacturing network, and strong risk management framework, Cipla is well-positioned to navigate the challenges posed by tariffs and other trade-related issues. The company’s consistent growth and performance demonstrate its ability to adapt to changing market conditions, and it is likely to continue to deliver strong results in the future. Overall, Cipla’s diversified model and strong manufacturing capabilities make it a resilient and attractive investment opportunity.
Global Digoxin Industry Analysis: An In-Depth Report Featuring Key Players Such as Pfizer, Novartis, and Mylan
The Global Digoxin Market study, recently introduced by HTF MI, provides a comprehensive overview of the product and industry scope, as well as an in-depth analysis of the market outlook and status from 2025 to 2031. The market is segmented by key regions, including North America, South America, Europe, Asia Pacific, and the Middle East and Africa.
The global Digoxin market was valued at USD 1.5 billion in 2024 and is expected to reach USD 2.4 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 6.1% from 2025 to 2031. The market is driven by the increasing prevalence of heart conditions, such as atrial fibrillation and congestive heart failure, particularly in aging populations. Technological advancements in cardiac monitoring and diagnostics have also enabled more precise dosage and monitoring of digoxin.
The major companies operating in the Digoxin market include Pfizer Inc., Merck & Co., Inc., Cipla Limited, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., and Lupin Limited.
The market is segmented by application (tablet product and injection product) and by type (purity above 98% and purity below 98%). North America is the dominating region, while Asia-Pacific is the fastest-growing region. The market is expected to grow due to the increasing demand for digoxin in emerging markets, investments in healthcare infrastructure, and the development of digital health tools for drug monitoring and adherence.
However, the market is also restrained by the availability of alternative treatments, adverse drug reactions, and stringent regulatory guidelines. The major challenges facing the market include side effects, such as digoxin toxicity, and complex interactions with other medications.
The report provides an in-depth analysis of the market, including a five-forces analysis and a PESTLE analysis, which examines the political, economic, social, technological, legal, and environmental factors affecting the market. The report also provides a detailed analysis of the market segmentation, competitive analysis, and market structure and worth analysis.
Overall, the Global Digoxin Market study provides a comprehensive overview of the market, including its drivers, restraints, challenges, and opportunities. The report is an essential resource for companies operating in the Digoxin market, as well as for investors, researchers, and policymakers.
Key Takeaways:
– The global Digoxin market is expected to reach USD 2.4 billion by 2031, with a CAGR of 6.1% from 2025 to 2031.
– The market is driven by the increasing prevalence of heart conditions and technological advancements in cardiac monitoring and diagnostics.
– North America is the dominating region, while Asia-Pacific is the fastest-growing region.
– The market is restrained by the availability of alternative treatments, adverse drug reactions, and stringent regulatory guidelines.
– The report provides an in-depth analysis of the market, including a five-forces analysis and a PESTLE analysis.
Market Size:
– Global Digoxin market size was valued at USD 1.5 billion in 2024.
– Expected to reach USD 2.4 billion by 2031.
– CAGR of 6.1% from 2025 to 2031.
Segmentation:
– By Application: Tablet product and injection product.
– By Type: Purity above 98% and purity below 98%.
– By Geography: North America, South America, Europe, Asia Pacific, and the Middle East and Africa.
Key Players:
– Pfizer Inc.
– Merck & Co., Inc.
– Cipla Limited
– F. Hoffmann-La Roche Ltd.
– Abbott Laboratories
– Novartis AG
– Mylan N.V.
– Teva Pharmaceutical Industries Ltd.
– Dr. Reddy’s Laboratories Ltd.
– Lupin Limited.
Regional Analysis:
– North America
– South America
– Europe
– Asia Pacific
– Middle East and Africa.
The five forces analysis includes:
– Bargaining power of buyers
– Bargaining power of suppliers
– Threat of new entrants
– Threat of substitutes
– Threat of rivalry.
The PESTLE analysis includes:
– Political
– Economic
– Social
– Technological
– Legal
!- Environmental.
Lupin Splits Off Its Consumer Healthcare Business to Form Independent Company
Lupin, a leading pharmaceutical company, has created a new subsidiary called LupinLife Consumer Healthcare Ltd to house its consumer healthcare business. This move is in line with a growing trend among pharmaceutical companies, both in India and globally, to separate their consumer health operations from their prescription drug businesses. The goal is to better target the rapidly expanding self-care market in India. Anil Kaushal will lead the new subsidiary as CEO, bringing strategic focus and agility to Lupin’s consumer health portfolio.
The separation of the consumer healthcare business from the prescription drug business allows for more targeted investments and a dedicated approach to building strong consumer brands in the over-the-counter (OTC) space. Lupin’s OTC consumer healthcare business contributed ₹148 crore to the company’s total standalone revenue of ₹14,666 crore in FY24. The new subsidiary has a strong portfolio of scientifically formulated brands, including Softovac, Beplex Forte, Corcium, and Aptivate, which are positioned to leverage the rising demand for preventive healthcare and wellness in India.
The pharmaceutical sector is witnessing a trend of spinning off consumer health units, as companies recognize the need for separate business models to cater to prescription drugs and OTC healthcare products. This allows companies to streamline operations and adopt more FMCG-style promotion strategies tailored for consumer health products, while maintaining focus on their traditional pharma businesses. Companies such as Cipla, Glenmark, Mankind Pharma, and Sanofi have already adopted similar strategies.
The formation of LupinLife Consumer Healthcare Ltd reflects the company’s long-term vision of adapting to evolving healthcare needs and market dynamics in India. With this move, Lupin joins a broader industry shift that seeks to unlock value and accelerate growth in two distinct but complementary healthcare markets – prescription pharmaceuticals and consumer wellness products. The company’s move is expected to enable it to sharpen its focus on prescription drugs while allowing the OTC arm to thrive independently in a fast-growing and competitive consumer healthcare market.
The US Food and Drug Administration has issued a single observation for Cipla’s Bommasandra manufacturing facility.
The US Food and Drug Administration (USFDA) has issued a single observation for Cipla’s Bommasandra facility, which is a pharmaceutical manufacturing plant located in Karnataka, India. The observation was made after the USFDA conducted an inspection of the facility from February 14 to February 18, 2022.
The USFDA issues observations under its Form 483, which is a list of conditions or practices that are required to be corrected in order to comply with the agency’s regulations. In this case, the single observation issued to Cipla’s Bommasandra facility indicates that the company has been found to be in compliance with most of the USFDA’s regulations, with only one minor issue that needs to be addressed.
The USFDA’s observation is related to the company’s quality control procedures, which are designed to ensure the purity, potency, and safety of the pharmaceutical products manufactured at the facility. While the observation does not specify the exact nature of the issue, it is likely related to a minor deviation from the company’s standard operating procedures (SOPs) or a failure to properly document certain quality control activities.
Cipla, which is one of India’s largest pharmaceutical companies, has stated that it is taking steps to address the observation and ensure that the facility is in full compliance with the USFDA’s regulations. The company has a strong track record of compliance with regulatory requirements and has previously received approvals from the USFDA for several of its products.
The issuance of a single observation is not uncommon, and it is seen as a minor setback for the company. In fact, many pharmaceutical companies receive observations from the USFDA during the course of an inspection, and it is up to the company to address the issue and ensure that it is in compliance with the agency’s regulations.
Overall, the USFDA’s observation of Cipla’s Bommasandra facility is a normal part of the regulatory process, and it does not necessarily indicate any major issues with the company’s quality control procedures or its ability to manufacture safe and effective pharmaceutical products. The company will likely address the observation and continue to operate the facility in accordance with the USFDA’s regulations.
Amit Patel has been promoted to lead Consumer Marketing Excellence as its new Head.
Amit Patel has been promoted to Head of Consumer Marketing Excellence at Cipla India, a leading pharmaceutical company. In his new role, Patel will be responsible for driving consumer marketing across various therapeutic areas, with a focus on building patient-centric and insight-led narratives. He expressed his excitement and gratitude for the opportunity, reflecting on his journey so far and the impact of his previous campaigns, which aimed to shift perceptions, build awareness, and create connections between patients and therapies.
Patel has over 15 years of experience in marketing and brand strategy, having worked across geographies and industries. Prior to joining Cipla, he held key positions at several companies, including Dabur International Ltd, VLCC International LLC, and Karan Communications, where he began his career as a Creative Coordinator. His professional strengths include critical thinking, public relations, digital marketing, brand development, and strategic planning.
As Head of Consumer Marketing Excellence, Patel will leverage his expertise to drive impactful and purpose-driven ideas at scale. He is committed to strengthening Cipla’s commitment to building patient-centric narratives and contributing to the company’s legacy of caring for life. Patel’s promotion is a testament to his hard work and dedication, and he is looking forward to the new challenges and opportunities that his expanded role will bring.
Patel’s experience and skills will be valuable assets to Cipla as the company continues to navigate the evolving healthcare landscape. His ability to think critically and develop effective marketing strategies will help drive growth and innovation in the company’s consumer marketing efforts. With his new role, Patel is poised to make a significant impact at Cipla and contribute to the company’s mission of improving the lives of patients and communities. Overall, Patel’s promotion is a significant development for Cipla, and his expertise and leadership will be instrumental in shaping the company’s consumer marketing efforts in the years to come.
The Indian market for active pharmaceutical ingredients has experienced significant revenue generation.
The India Active Pharmaceutical Ingredients (API) market is expected to experience significant growth, with an estimated value of USD 14.81 billion in 2025 and a projected value of USD 25.23 billion by 2032, at a compound annual growth rate (CAGR) of 7.9%. This growth is driven by increasing demand for pharmaceuticals, innovation, and the presence of key players in the market.
The report provides a comprehensive analysis of the India Active Pharmaceutical Ingredients market, including market size, revenue, production, and CAGR. It also highlights the competitive landscape, with key players such as Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin, Cipla, and Sun Pharmaceutical Industries. The report provides a detailed review of major players, covering their financials, product benchmarking, and competitive strategies.
The market is segmented by manufacturer, synthesis type, drug type, application, product type, and formulation. The report also analyzes the geographical landscape of the market, with a focus on North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
The report identifies key drivers and trends in the market, including technological advancements, regulatory and policy shifts, and emerging industry trends. It also highlights the opportunities and challenges in the market, including supply chain issues and evolving consumer behavior.
The report provides actionable insights and quantitative analysis of market segments, trends, estimations, and dynamics. It also includes Porter’s Five Forces analysis for strategic decision-making and segmentation analysis to identify market opportunities.
The key benefits of the report include:
* Quantitative analysis of market segments, trends, estimations, and dynamics
* Insights into key drivers, restraints, and opportunities
* Porter’s Five Forces analysis for strategic decision-making
* Segmentation analysis to identify market opportunities
* Revenue mapping of major countries by region
* Benchmarking and positioning of market players
* Analysis of regional and global trends, key players, and growth strategies
The report is a valuable resource for industry leaders, investors, and decision-makers, providing a comprehensive and detailed analysis of the India Active Pharmaceutical Ingredients market. It is available for purchase, with a 25% discount for a limited time.
Cipla Limited and its division EMEU, have been honoured at the prestigious Healthcare Asia Pharma Awards 2025.
Cipla EMEU and Cipla Limited have been recognized at the Healthcare Asia Pharma Awards 2025 for their innovative initiatives. Cipla EMEU received the ESG Program of the Year – India award for its Ahead & Apart campaign, which promotes sustainable practices in the healthcare ecosystem. The campaign has three core strategies: communication, certification, and sustainable reminders, and has already engaged over 27,000 healthcare professionals (HCPs) across seven countries. The initiative aims to encourage the adoption of Environmental, Social, and Governance (ESG) practices and has earned several achievements, including the prestigious Zero Waste to Landfill Certification.
On the other hand, Cipla Limited received the Most Differentiated Service of the Year – India award for its Breathefree Digital Educator initiative. This platform provides personalized and tech-enabled guidance to patients on how to use their inhalers correctly, addressing the critical barrier to effective treatment in respiratory healthcare. Patients can access the platform by scanning a QR code on their inhaler packaging, which directs them to a live video consultation with a healthcare professional. The platform tracks patient engagement and provides valuable insights to refine educational strategies.
Both initiatives demonstrate the companies’ commitment to innovation and excellence in the pharmaceutical industry. The Ahead & Apart campaign strengthens Cipla’s reputation as a global sustainability leader, while the Breathefree Digital Educator initiative delivers real-world impact by helping patients breathe better and live healthier lives. The Healthcare Asia Pharma Awards recognizes companies in Asia that have redefined pharmaceutical excellence and gives recognition to game-changers and visionaries who possess unwavering commitment to innovation and excellence.
The awards are presented by Healthcare Asia Magazine, and the full list of winners can be viewed on their website. The magazine also invites companies to join the 2026 awards programme and be recognized for their innovative initiatives that have enhanced their business and made remarkable contributions to the pharmaceutical industry. The recognition of Cipla EMEU and Cipla Limited’s initiatives serves as a testament to their dedication to a healthier and greener future, and their commitment to making a positive impact in the lives of patients and healthcare professionals alike.
Cipla to Report Q4 FY 2025 Earnings on May 13, Dividend Payment Possible
Pharmaceutical company Cipla has announced the date for its earnings release for the fourth quarter and full year ended March 31, 2025. The company’s Board of Directors is scheduled to meet on Tuesday, May 13, 2025, to consider and approve the standalone and consolidated audited financial results. Based on its past trend, Cipla is expected to announce the results post-market hours on May 13.
The company also indicated that it may recommend a final dividend for FY25 during the upcoming board meeting. Cipla has a history of rewarding shareholders with healthy dividend payouts, with a dividend of ₹13 declared in 2024, up from ₹8.50 in 2023 and ₹5 in 2022.
Additionally, Cipla announced that its trading window for dealing in securities will remain closed from April 1 to May 15, 2025, in compliance with insider trading regulations and in view of the upcoming financial results.
Looking back, Cipla’s Q3 results for FY25 showed a 49% jump in consolidated net profit to Rs 1,571 crore, compared to Rs 1,056 crore in the same quarter a year ago. Revenue from operations grew 7% YoY to Rs 7,073 crore. Sequentially, the net profit rose 21% from Rs 1,303 crore in Q2 FY25, while revenue showed a marginal increase from Rs 7,051 crore.
A sudden surge in demand for Doxorubicin may send market momentum soaring, with influential companies like Merck & Co., Lupin, and Cipla playing a pivotal role.
The latest survey on the Doxorubicin market has been conducted to provide a comprehensive analysis of the market’s performance, competitive environment, and market size. The report covers the period from 2019 to 2024 and provides a forecast till 2031. The market size is estimated to be around USD 2.3 million in 2024 and is expected to grow at a CAGR of 5.5% to reach USD 3.4 million by 2031.
The report profiles key and emerging players in the Doxorubicin market, including Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Cipla Inc., Lupin, Cadila Pharmaceuticals, SRS Life Sciences, and Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co., Ltd. The report also provides a detailed analysis of the market segments, including Lyophilized Powder and Doxorubicin Injection, as well as applications such as Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, and Other.
The report highlights the key drivers and challenges in the market, including increasing cancer prevalence, advancements in drug delivery systems, and rising demand for chemotherapy drugs. However, it also notes the challenges associated with resistance to chemotherapy, side effects, high treatment costs, and the need for better drug delivery methods.
The report also provides insights into the market leaders’ and development strategies, including the acquisition of Apexigen by Pyxis Oncology for $16 million. This acquisition positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation and expands its clinical pipeline into phase 2 in select solid tumor types.
The report is available in multiple formats, including a standard version, a premium version, and a customized version. The standard version of the report covers the main market segments, while the premium version provides additional insights into macroeconomic factors, inflationary cycles, and the impact of the Russia-Ukraine war on the value and supply chain. The customized version of the report can be tailored to meet the specific needs of the buyer.
Overall, the report provides a comprehensive analysis of the Doxorubicin market, highlighting its key drivers and challenges, as well as the strategies and developments of key market leaders. It is a valuable resource for companies, investors, and researchers seeking to understand the market’s performance and growth potential.
Cipla Lacrosse up a massive partnership with Formosa, securing a sweeping deal spanning 11 countries for their clobetasol offerings.
Cipla, a leading global pharmaceutical company, has signed an exclusive licensing agreement to expand its ophthalmology portfolio and global offerings. The agreement involves the acquisition of Formosa Pharmaceuticals’ US FDA-approved clobetasol propionate 0.05% ophthalmic suspension (APP13007).
Under the agreement, Cipla will have exclusive rights to market and distribute APP13007 in India and South Africa. The product is a corticosteroid designed for the treatment of various ocular inflammatory conditions, including inflammatory posterior uveitis, chorioretinitis, and anterior uveitis.
With this new addition, Cipla’s ophthalmology portfolio is poised to benefit from the growing demand for treatment options in this area. Clobetasol propionate 0.05% ophthalmic suspension has already received US FDA approval, making it a valuable asset for Cipla’s global offerings.
The expansion of Cipla’s ophthalmology portfolio is strategic, as the company continues to diversify its product range and strengthen its presence in key markets. The agreement reflects Cipla’s commitment to investing in products that cater to unmet medical needs and address specific therapeutic areas.
The inclusion of APP13007 in Cipla’s portfolio is expected to enhance the company’s competitiveness in the ophthalmology space, particularly in India and South Africa. The deal also underscores Cipla’s ability to identify and acquire complementary products that align with its business strategy.
The agreement with Formosa Pharmaceuticals marks a significant milestone in Cipla’s ongoing efforts to expand its global footprint and expand its product offerings. This development is likely to be seen as a further endorsement of Cipla’s position as a leading healthcare company, committed to delivering high-quality treatments to patients worldwide.
Overall, the exclusive licensing agreement with Formosa Pharmaceuticals is a significant step towards Cipla’s continued growth and expansion, as it bolsters its ophthalmology portfolio and increases its global presence.
Eli Lilly expands its global footprint by introducing Mounjaro, a groundbreaking weight management medication, to the Indian market.
Eli Lilly & Co. has launched its anti-obesity drug Mounjaro in India, making it the country’s first treatment of its kind. The drug, which is used to treat obesity and type-2 diabetes, works by activating hormones that help reduce the amount of sugar in the blood and slow digestion. Mounjaro is priced at ₹3,500 to ₹4,375 per month, depending on the dosage.
The company has faced competition from other foreign pharma companies, with plans to introduce similar products in the growing market. However, Mounjaro’s unique pricing strategy, which is expected to be around 14,000-17,500 per month, makes it an attractive option for Indian patients.
The demand for GLP-1 drugs, which help reduce weight, has boomed, with the market expected to reach $100 billion by 2030. However, rival semaglutide (Ozempic) goes off-patent in 2026, and generics makers like Cipla, Dr Reddy’s, Lupin, Natco Pharma, Mankind Pharma, and Biocon are gearing up to launch cheaper generic copies.
Despite this, experts expect Mounjaro to be a hit in India, given the high demand for weight loss drugs. According to a senior diabetologist, a significant percentage of his patients are overweight, and the use of Mounjaro could lead to a 15-20% pickup in patients with type-2 diabetes.
In addition, the growing number of people with obesity in India, from 180 million in 2021 to 450 million by 2050, could lead to increased demand for weight loss drugs like Mounjaro. The market for GLP-1 drugs for patients with diabetes in India has already doubled to $3.6 billion in 2024, driven by unauthorized use of drugs like Ozempic and Mounjaro through the grey market.